Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PN-101 in Refractory Polymyositis or Dermatomyositis
NCT07122648Phase 2Not yet recruiting
- Sponsor
- Paean Biotechnology
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of PN-101 in polymyositis (PM), dermatomyositis (DM), sponsored by Paean Biotechnology. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
PN-101
03
Conditions
polymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on NCT07122648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07122648.